HLTH 252 Week 3 Case Study Analysis 1 Example

The Tranquilizer in the Fentanyl Supply: A Case Study Analysis of Xylazine and Its Public Health Consequences

Introduction

Friedman et al. (2022) describe how xylazine, a sedative used by veterinarians on horses and cattle, moved from the street drug supply of Puerto Rico and Philadelphia into overdose deaths across the United States. Xylazine is not an opioid, but it is now usually mixed with illicitly made fentanyl. This analysis examines how common it has become, why it is dangerous, what public health problems it creates, how Christians might respond morally and what evidence suggests can reduce harm.

Prevalence

The article combined ethnographic work in Philadelphia with a search of overdose death records in ten jurisdictions. Xylazine was present in 0.36% of overdose deaths in 2015 and 6.7% in 2020, with the highest rates in Philadelphia (25.8% of deaths), Maryland (19.3%) and Connecticut (10.2%). Fentanyl was found in 98.4% of the deaths involving xylazine, and cocaine, benzodiazepines, heroin and alcohol were also common (Friedman et al., 2022). National data confirm the trend. Kariisa et al. (2023) used the federal overdose reporting system and found that among 21 jurisdictions, the monthly share of fentanyl-involved deaths with xylazine detected rose 276%, from 2.9% to 10.9%, between January 2019 and June 2022, with the highest detection in the Northeast. Because many jurisdictions do not routinely test for xylazine, these figures likely understate its presence.

Why Xylazine Is Dangerous

Hart and Ksir (2018) explain that depressants slow the activity of the central nervous system, and that combining depressants, or a depressant with an opioid, increases the risk of dangerous sedation and breathing problems because their effects add together. Xylazine fits that pattern. Kariisa et al. (2023) note that it can cause central nervous system depression, slowed breathing, slow heart rate and low blood pressure, and that chronic use may cause severe withdrawal and skin wounds. People who inject drugs in Philadelphia told researchers that xylazine was sought after because it lengthens fentanyl's short effect, but they linked it to soft tissue infections and overdoses that did not respond to naloxone (Friedman et al., 2022).

Public Health Issues

Xylazine creates three problems for public health. First, naloxone reverses only the opioid part of an overdose, so a person may keep breathing but remain deeply sedated, which can confuse bystanders and responders. Second, xylazine-related wounds can become severe and are hard to treat when people avoid clinics because of stigma. Third, surveillance is weak: without routine testing, health departments cannot see where xylazine is spreading. The problem also falls unevenly. The highest rates have appeared in older East Coast drug markets, where many people who inject drugs are already living with chronic wounds, housing instability and limited access to medical care, so xylazine adds new harm to people who already carry the heaviest burdens. A drug that naloxone cannot reverse and many laboratories do not test for can spread for years before anyone counts it.

Moral and Biblical Positions

Some people respond to stories like this with contempt for those who use drugs. The parable of the good Samaritan challenges that response. A man lay wounded by the road, and while two religious leaders passed by, a Samaritan bound up his wounds, carried him to an inn and paid for his care (English Standard Version Bible, 2001/2016, Luke 10:30-37). Jesus told the parable to answer the question of who our neighbor is. People with xylazine wounds are, quite literally, wounded people by the side of the road. A Christian response does not approve of drug misuse, but it insists on care, dignity and help toward recovery.

Evidence-Based Responses

Several responses follow from the evidence. Drug checking with test strips, now available for xylazine, can warn people about what is in their supply. Overdose response training should teach people to give naloxone and also rescue breathing and to call for emergency help, since sedation may persist. Health departments should add xylazine to routine postmortem and drug supply testing, as Kariisa et al. (2023) recommend. Wound care offered through syringe service programs and mobile clinics can reach people who will not visit a hospital, and each contact is a chance to offer treatment for opioid use disorder.

Conclusion

Xylazine shows how quickly the drug supply can change and how depressants become most dangerous in combination. Public health agencies must test for it, teach responses to it and treat its wounds, and Christians are called to see the people affected as neighbors worth caring for. Because the drug supply will keep changing, the most lasting lesson may be the need for surveillance and services flexible enough to respond to whatever appears next.

References

English Standard Version Bible. (2016). Crossway. (Original work published 2001)

Friedman, J., Montero, F., Bourgois, P., Wahbi, R., Dye, D., Goodman-Meza, D., & Shover, C. (2022). Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. Drug and Alcohol Dependence, 233, 109380. https://doi.org/10.1016/j.drugalcdep.2022.109380

Hart, C. L., & Ksir, C. (2018). Drugs, society, and human behavior (17th ed.). McGraw-Hill Education.

Kariisa, M., O'Donnell, J., Kumar, S., Mattson, C. L., & Goldberger, B. A. (2023). Illicitly manufactured fentanyl-involved overdose deaths with detected xylazine: United States, January 2019-June 2022. Morbidity and Mortality Weekly Report, 72(26), 721-727. https://doi.org/10.15585/mmwr.mm7226a4